Peroxynitrite activates ERK via Raf-1 and MEK, independently from EGF receptor and p21Ras in H9C2 cardiomyocytes by Pesse, B. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Peroxynitrite activates ERK via Raf-1 and MEK, independently 
from EGF receptor and p21Ras in H9C2 cardiomyocytes. 
Authors: Pesse B, Levrand S, Feihl F, Waeber B, Gavillet B, Pacher P, 
Liaudet L 
Journal: Journal of molecular and cellular cardiology 
Year: 2005 May 
Volume: 38 
Issue: 5 
Pages: 765-75 
DOI: 10.1016/j.yjmcc.2005.02.020 
 
Peroxynitrite activates ERK via Raf-1 and MEK, independently
from EGF receptor and p21Ras in H9C2 cardiomyocytes
B. Pessea,1, S. Levranda,b,1, F. Feihlb, B. Waeberb, B. Gavilletc, P. Pacherd, and L.
Liaudeta,*
aDivision of Critical Care, Department of Internal Medicine, BH 10-982, University Hospital, 1011 Lausanne,
Switzerland bDivision of Clinical Pathophysiology and Medical Teaching, Department of Internal Medicine,
University Hospital, 1011 Lausanne, Switzerland cDepartment of Pharmacology and Toxicology, University
Hospital, 1011 Lausanne, Switzerland dNational Institutes of Health, NIAAA, Laboratory of Physiologic
Studies, 5625 Fishers Lane MSC 9413, Room 2N17, Bethesda, MD 20892-9413, USA
Abstract
Peroxynitrite is a potent oxidant and nitrating species proposed as a direct effector of myocardial
damage in a wide range of cardiac diseases. Whether peroxynitrite also acts indirectly, by modulating
cell signal transduction pathways in the myocardium, has not been investigated. Here, we examined
the ability of peroxynitrite to activate extracellular signal-related kinase (ERK), a MAP kinase which
has been linked with hypertrophic and anti-apoptotic responses in the heart, in cultured H9C2
cardiomyocytes. Peroxynitrite elicited a concentration-and time-dependent activation of ERK,
secondary to the upstream activation of MEK 1 (ERK kinase). Activation of MEK-ERK by
peroxynitrite was related to the upstream activation of Raf-1 kinase, as ERK and MEK
phosphorylation were prevented by the Raf-1 inhibitor BAY43–9006. These effects of peroxynitrite
were not associated with the activation of p21Ras, known as a common signaling target of cellular
oxidative stress. In contrast to ERK activation mediated by the epidermal growth factor (EGF), ERK
activation by peroxynitrite was not prevented by AG1478 (EGF receptor inhibitor). Peroxynitrite
acted through oxidative, but not nitrative chemistry, as ERK remained activated while nitration was
prevented by the flavanol epicatechin. In addition to ERK, peroxynitrite also potently activated two
additional members of the MAP kinase family of signaling proteins, JNK and p38. Thus, peroxynitrite
activates ERK in cardiomyocytes through an unusual signaling cascade involving Raf-1 and MEK
1, independently from EGFR and P21Ras, and also acts as a potent activator of JNK and p38. These
results provide the novel concept that peroxynitrite may represent a previously unrecognized
signaling molecule in various cardiac pathologies.
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1. Introduction
Mitogen-activated protein kinases (MAPKs) are a family of signaling proteins linking
extracellular stimuli to various cellular responses. Three major classes of MAPKs have been
described, including p38 MAP kinase, c-Jun NH2-terminal kinase (JNK), and extracellular
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signal-regulated kinase (ERK), which exists as two major isoforms, ERK 1 and ERK 2 (p44
and p42 MAP kinase) [1]. While p38 and JNK are activated by environmental stress, ERK is
involved in the signaling pathways triggered by growth factors, such as the epidermal growth
factor (EGF), via the activation of EGF receptor (EGFR), Raf-1 kinase and MEK 1 [2]. ERK
activation has recently emerged as an important mechanism involved in various cardiac
pathologies, including ischemia–reperfusion, anthracycline cardiotoxicity and severe heart
failure [3], where ERK has been shown to promote cardiac hypertrophy and to reduce
cardiomyocyte apoptosis [4,5]. The stimuli responsible for myocardial ERK activation in these
conditions are only poorly defined, and the signaling pathway leading to ERK activation in the
myocardium is far from being elucidated [6]. Further studies are therefore needed to define
potential mechanisms of ERK activation in the heart [3].
Peroxynitrite (ONOO−), a strong oxidant and nitrating species formed by the near-diffusion-
limited reaction between superoxide (O2•−) and nitric oxide (NO•) [7], has been recently found
to be a key effector of myocardial damage and dysfunction in several conditions, most notably
myocardial infarction [8], anthracycline cardiomyopathy [9] and chronic heart failure [10].
ONOO− is generally considered to act as a directly biotoxic molecule, but indirect effects,
related to the modulation of redox sensitive cell signaling pathways might also account for
some of its biological actions in the heart. Since no association between ONOO− and ERK
activation in the myocardium has been reported so far, we conducted the present study to detect
a possible link between ONOO− and the ERK signaling pathway in H9C2 rat cardiomyocytes.
H9C2 cells were used, as they are morphologically similar to embryonic cardiocytes and are
recognized as a well suited model for the study of cardiomyocyte biology [11]. Due to potential
limitations associated with the use of a clonal cell line, the effects of ONOO− on the ERK
pathway were also addressed in primary ventricular cardiomyocytes isolated from mouse heart.
In addition, we evaluated whether ONOO−might activate other members of the MAP kinase
family, including p38 and JNK, which have been associated with pro-apoptotic responses in
cardiomyocytes [6]. Our findings indicate that ONOO− acts via an unusual signaling pathway
to induce ERK phosphorylation and activation, and also strongly activates the phosphorylation
of p38 and JNK. These observations reveal a previously unrecognized role of ONOO− as a
signaling molecule in cardiomyocytes.
2. Material and methods
2.1. Cell culture
H9C2 cells, a clonal line derived from rat heart (ATCC, Manassas, VA) were grown (5%
CO2, 37 °C) in Dulbecco’s modified Eagles medium (Gibco BRL, Invitrogen, Basle,
Switzerland) supplemented with 10% fetal calf serum. Cells were cultured to 80% confluence
in 10 cm culture dishes or 6-well plates and were serum-starved 24 h before the experiments.
Some experiments were also performed using primary ventricular mouse cardiomyocytes.
Briefly, 8–10 weeks old C57BL/6 male mice were anesthetized with pentobarbital (80 mg
kg−1). Hearts were removed and perfused (at 37 °C) for 5 min with modified Krebs–Henseleit
bicarbonate (KHB) buffer (mM: NaCl 35, KCl 4.7, KH2PO4 1.2, Na2HPO4 16, NaHCO3 25,
HEPES 10, glucose 10, sucrose 134, pH 7.4). The heart was then perfused for 12 min with
KHB containing 0.1% (w/v) collagenase type II (Sigma). After perfusion, the left ventricle was
minced and the cells further digested with collagenase before being filtered through a nylon
mesh (300 μm). The cardiomyocytes were pelleted by 2 successive centrifugations (220 rpm,
1 min), and were used for the experiments described below immediately after isolation.
2.2. Stimulation with ONOO−
ONOO− was obtained as a 50 mM stock in 0.3 M NaOH (Upstate Biotechnology, Inc., Lake
Placid, NY). All dilutions of the stock solution were made in the same concentration of NaOH.
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Prior to experimentation, ONOO− was quantitated spectrophotometrically (extinction
coefficient at 302 nm = 1670 M−1 cm−1 [12]). For stimulation with ONOO−, cells were washed
once and placed in phosphate-buffered saline (PBSgluc) (50 mM sodium phosphate, 90 mM
NaCl , 5 mM KCl and 5 mM glucose, pH 7.4), to avoid reactions of ONOO− with media
constituents [2,13,14]. ONOO− was delivered as a single bolus at a 1:100 dilution against one
side of the dish, while rapidly swirling the medium to ensure optimal exposure of the cells to
ONOO−. ONOO− was used at concentrations ranging from 50 to 500 μM, which agrees with
previous studies evaluating the effects of ONOO− on various cell signaling pathways in vitro
[2,13,15,16]. Such concentrations of ONOO− are physiologically relevant, as it has been
estimated that the rate of peroxynitrite generation may reach up to 1 mM min−1 in an inflamed
organ (lung) in vivo. [17]. Control experiments were made using a solution of decomposed
ONOO−, made by leaving the solution of ONOO− overnight at room temperature [18], which
contains similar amounts of nitrite, nitrate and NaOH as the ONOO− solution, but no
ONOO−.
2.3. Treatment of cells
To address the role of the various signaling intermediates possibly involved in ERK activation
by ONOO−, cells were treated with the following inhibitors before ONOO− stimulation:
AG1478, a specific inhibitor of EGFR tyrosine kinase (100 nM, Calbiochem, San Diego, CA),
BAY 43–9006, a Raf-1 kinase inhibitor (5 μM, Calbiochem) [19], and PD98059, a specific
MEK 1 inhibitor (50 μM, Calbiochem). All inhibitors were added to the cells 1 h before
ONOO− stimulation and remained in the medium until the end of the experiments. In additional
experiments, cells were pretreated with the farnesyl transferase inhibitor FPTII (Calbiochem,
20 μM, 24 h pretreatment), a potent and selective inhibitor of Ras GTPase [20]. Also, to
evaluate the potential role of tyrosine nitration in the effects of ONOO−, cells were pretreated
for 1 h with the flavanol (−)-epicatechin (Sigma), a specific inhibitor of tyrosine nitration
[15], at concentrations ranging from 50 to 250 μM.
2.4. Western blot analysis
After ONOO− stimulation, cells were scraped in lysis buffer (Tris–HCl 10 mM, NP40 0.5%,
NaCl 0.15 M, Na3VO4 1 mM, NaF 10 mM, PMSF 1 mM, EDTA 1 mM, aprotinin 10 μg
ml−1, leupeptin 10 μg ml−1 and pepstatin 1 μg ml−1). Proteins (10–20 μg) were separated by
SDS-PAGE, transferred to nitrocellulose membrane, and blocked for 1 h at room temperature
with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20. The membrane
was then incubated overnight at 4 °C with an appropriate dilution of anti-phospho-ERK 1/2
(p44 and p42), anti-phospho-MEK 1/2, anti-phospho JNK1/2 (p54 and p46), anti-phospho-
p38, anti-ERK 1/2, anti-MEK 1/2, anti-JNK1, anti-p38 (all from Cell Signaling, Beverly, MA)
or anti-nitrotyrosine (Upstate Biotechnology) primary antibody, followed by incubation for 1
h with a 1:5000 dilution of the appropriate horseradish peroxidase-conjugated secondary
antibody (Bio-Rad, Hercules, CA). The immunoblot signal was visualized using enhanced
chemiluminescence (ECL,Amersham Biosciences, Otelfingen, Switzerland). Densitometric
analysis of ECL autoradiographs were performed using a Personal Densitometer and TotalLab
Software.
2.5. Immunoprecipitation and ERK 1/2 kinase assay
ERK 1/2 activity was measured using a non-radioactive p42/p44 MAP Kinase assay kit (Cell
Signaling, Beverly, MA), according to the manufacturer’s instructions. Briefly, phospho-ERK
1/2 was immuno-precipitated from 200 μg of protein with an immobilized anti-phospho-
ERK1/2 mAb at 4 °C overnight. The immunoprecipitate was resuspended in kinase buffer
containing 25 mM Tris (pH 7.5), 5 mM β-glycerophosphate, 10 mM MgCl2, 0.1 mM
Na3VO4, and 2 mM DTT. The kinase reaction was performed using 2 μg Elk-1 fusion protein
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(a specific substrate of phospho-ERK 1/2) and 0.2 mM ATP at 30 °C for 30 min. The
phosphorylation of Elk-1 was then determined following immunoblotting, by using a primary
polyclonal anti-phospho-Elk-1 antibody (1:1000) and chemiluminescence detection.
Densitometric analysis was performed as above.
2.6. Ras activation assay
Ras activation was determined using a non-radioactive assay kit (Upstate, Lake Placid, NY,
USA), as previously described [21]. Briefly, activated P21Ras from H9C2 lysates was
precipitated (45 min, 4 °C) using a GST fusion protein corresponding to the Ras binding domain
of Raf-1 (residues 1–149) conjugated to agarose beads. After extensive washing, the beads
were boiled in 2× Laemmli buffer, and the eluted proteins were resolved by SDS-PAGE,
transferred to nitrocellulose membranes, at 4 °C overnight, and visualized by using a goat anti-
mouse secondary antibody conjugated to horseradish peroxidase (Bio-Rad) and a
chemiluminescence detection system. Total p21 ras immunoblotting was used as an internal
control. Densitometric analysis was performed as above. Positive and negative controls were
obtained by loading cell extracts with either GTPcS (a non-hydrolyzable analog of GTP,
positive control) or GDP (negative control).
2.7. Presentation of data and statistical analysis
Results of the densitometric analyses are shown as mean ± S.E.M. In the experiments
comparing only two conditions, statistical analysis was performed using Student’s t-test, and
a P value < 0.05 was considered significant. In all the other experiments, statistical analysis
was performed using analysis of variance for repeated measurements, after logarithmic
transformation of the densitometric data to stabilize variances. When the F value was
significant, further pairwise comparisons were carried out with an adjustment for multiple
comparison made using the Bonferroni procedure, as modified by Hochberg and Benjamini
[22]. The alpha level of all tests was set at 0.05.
3. Results
3.1. Activation of ERK1/2 by ONOO−
Incubation of cells with 50 μM or more of ONOO− for 15 min resulted in a concentration-
dependent increased phosphorylation of ERK1/2 (p44/p42, Fig. 1A), with no change in the
level of non-phosphorylated ERK 1/2. At 500 μM, ONOO− (Fig. 1B) elicited a time-dependent
ERK phosphorylation, starting at 2 min and reaching a maximum between 15 and 30 min. The
phosphorylation of ERK by ONOO− was associated with a stimulated activity of ERK, as
evidenced by an increased phosphorylation of the transcription factor Elk-1 in the ERK kinase
assay experiment (Fig. 1c). ERK phosphorylation and activation were not observed in cells
stimulated with decomposed ONOO− (DC). As illustrated in Fig. 2, stimulation with 500 μM
ONOO− for 15 min also induced a significant phosphorylation of both p44 and p42 MAP kinase
in primary mouse ventricular cardiomyocytes.
3.2. ERK 1/2 phosphorylation by ONOO− occurs via a MEK 1-dependent pathway
Treatment of cells with 500 μM ONOO− for 15 min resulted in a marked phosphorylation of
MEK 1 (Fig. 3A) with no changes in the level of non-phosphorylated MEK. The MEK inhibitor
PD98059 was used to investigate whether ERK phosphorylation induced by ONOO− depends
on MEK 1 phosphorylation. As shown in Fig. 3B, treatment of cells with 50 μM PD98059 for
1 h resulted in a significant inhibition of ERK 1/2 phosphorylation. These data indicate that
ERK phosphorylation by ONOO− depends completely on the upstream phosphorylation of
MEK 1 by ONOO−.
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3.3. Role of EGF receptor and Raf-1 kinase in the process of ERK 1/2 phosphorylation by
ONOO−
The typical signaling cascade leading to ERK activation by growth factors involves the
activation of growth factor receptors, Raf-1 kinase and MEK 1. This cascade was observed in
H9C2 cells upon stimulation with EGF (0.1 μg ml−1): after 15 min, ERK 1/2 was
phosphorylated, and this effect was abrogated when cells were pretreated withAG1478, an
EGFR inhibitor, BAY 43–9006, a Raf-1 kinase inhibitor, or PD98059 (Fig. 4A). In cells treated
with ONOO−, ERK phosphorylation was not influenced by AG1478 whereas it was prevented
by BAY 43–9006 and significantly reduced by PD 98059 (Fig. 4B). Also, the phosphorylation
of MEK 1 (Fig. 5A) and the kinase activity of ERK 1/2 (Fig. 5B) triggered by ONOO− remained
unaffected in the presence of AG1478 but was abolished by BAY 43–9006. These data indicate
that ONOO− triggers a signaling cascade involving Raf-1 kinase and MEK 1 to activate ERK,
independently from EGFR activation.
3.4. ONOO− does not induce the activation of p21Ras
P21Ras has been shown to act as a common signaling target of reactive free radicals and cellular
redox stress and some investigators reported that NO and NO-related species could stimulate
guanine nucleotide exchange on P21Ras [20,23,24]. Using a Ras activation assay, we found
that P21Ras was activated constitutively in H9C2 cells (Fig. 6A). Stimulation with ONOO− did
not activate further P21Ras at time-points ranging from 2 to 15 min. Furthermore, the activation
of ERK by ONOO− was not inhibited by FPT II, a specific inhibitor of P21Ras (Fig. 6B). Thus,
P21Ras does not represent a relevant intermediate in the pathway linking ONOO− stimulation
to ERK activation in H9C2 cells.
3.5. ONOO− activates ERK 1/2 independently of the nitration of tyrosine residues
As illustrated in Fig. 7, stimulation with 500 μM ONOO−for 15 min induced a widespread
nitration of cellular proteins. Nitration was completely inhibited by epicatechin, at
concentrations of 100 μM and above (Fig. 7A). However, pretreatment of cells with 100 μM
epicatechin did not affect ERK phosphorylation, implying that the latter was not due to
ONOO−-mediated tyrosine nitration (Fig. 7B, C).
3.6. ONOO− activates the phosphorylation of JNK and p38 in H9C2 cells
As illustrated in Fig. 8A. Incubation of H9C2 cells for 15 min with ONOO− activated the
phosphorylation of JNK p46 and p54, an effect that was significant at all concentrations of the
oxidant, whereas the levels of non-phosphorylated JNK1 were not influenced. We then
examined the time-course of this effect by stimulating cells with 500 μM ONOO−for periods
ranging from 2 to 60 min. As shown in Fig. 8B, JNK phosphorylation was significantly induced
from 5 to 60 min (p54) and from 2 to 60 min (p46) after ONOO−. Similarly to JNK, ONOO−
also significantly activated the phosphorylation of p38 MAP kinase at all time-points and all
concentrations (50 to 1000 μM) studied, while it did not change the cellular levels of non-
phosphorylated p38 (Fig. 9). Thus, ONOO− acts as a potent signaling molecule able to activate
all members of the MAP kinase family in H9C2 cardiomyocytes.
4. Discussion
In the present study, we provide the novel demonstration that ONOO− acts as a potent inducer
of ERK1/2 phosphorylation and ERK kinase activity in H9C2 cardiomyocytes (Fig. 1).
ONOO− also induced the phosphorylation of ERK in primary mouse ventricular
cardiomyocytes (Fig. 2), indicating that this effect was not an artifact related to the use of clonal
cell line. We then dissected the cascade leading to ERK activation in these conditions and found
an uncommon signaling mechanism triggered by ONOO−. In the typical pathway of ERK
Pesse et al. Page 5
J Mol Cell Cardiol. Author manuscript; available in PMC 2008 February 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
activation by growth factors such as the EGF, ERK1/2 phosphorylation occurs through a
cascade involving EGF receptor (EGFR) tyrosine kinase and the downstream activation of
Raf-1 and MEK1/2. EGF stimulation of H9C2 cells resulted in this typical cascade (Fig. 4), as
EGF-dependent activation of ERK 1/2 was inhibited by AG1478, a specific EGFR inhibitor,
by BAY 43–9006, an inhibitor of Raf-1 kinase, and by PD 98059, an inhibitor of MEK1. Upon
stimulation with ONOO−, we found that ERK activation was associated with MEK
phosphorylation and was completely prevented by PD98059 (Fig. 3). Also, both MEK
phosphoryation and ERK activity were inhibited by BAY 43–9006 (Fig. 5), which indicates
that ONOO−-mediated ERK activation totally depends on MEK 1 phosphorylation, itself being
dependent on Raf-1 kinase. In contrast to EGF, the effects of ONOO− on ERK were not
influenced by AG1478, which supports that EGFR is not a relevant signaling intermediate in
the process of ERK activation by ONOO− in H9C2 cardiomyocytes. It is noteworthy that
ONOO− has also been found to activate ERK in fibroblasts, but through signaling pathways
independent from Raf-1 [2], or even independent from MEK-1, via a mechanism involving
protein kinase C [14]. Also, a previous report indicated that ONOO− could activate EGFR in
PC 12 cells, triggering the downstream activation of ERK [25]. Our data are in clear contrast
with these findings and thus indicate that the cellular targets of ONOO− critically depend on
the cell type studied.
We also examined the possibility that ONOO− might activate ERK via p21Ras, which has been
proposed to serve as a general signaling target of reactive free radicals and as a cellular sensor
of redox stress [20,24]. At variance with previous findings that ONOO− or SIN-1, a
peroxynitrite generator, induced the activation of p21Ras in human neutrophils [26] and murine
neural cells [27], we could not detect any increase in p21Ras activation upon ONOO− exposure
in H9C2 cells (Fig. 6).Also, we did not find any influence of FPTII, a highly selective and
potent inhibitor of Ras farnesyltransferase, on ERK phosphorylation by ONOO− indicating
that Ras is dispensable for ERK activation by peroxynitrite. This observation contrasts with
the requirement of Ras of other known activators of ERK in cardiomyocytes, such as
endothelin-1, phenylephrine and phorbol esters [6,28]. Thus, our findings introduce the novel
concept that an unusual, alternative pathway of ERK activation, which is independent from
p21Ras signaling, is triggered by ONOO− in cardiac muscle cells. If ONOO− can activate the
Raf-1/MEK/ERK pathway in the absence of p21Ras activation, one may wonder which
signaling intermediate uspstream from Raf-1 is activated by ONOO−. Raf-1 is a serine-
threonine kinase governed by complex regulatory mechanisms, which notably involve
phosphorylation at multiple amino acid residues [29]. Several kinases have been implicated in
the process of Raf-1 phosphorylation and activation, including src-family tyrosine kinases, the
phosphatidyl inositol 3 kinase (PI3K) and protein kinase C (PKC) [29,30]. It is here worth to
mention that recent investigations have indicated that ONOO− can activate src-tyrosine kinase
in endothelial and neural cells [31,32], PI3K in endothelial cells, fibroblasts and adipocytes
[13,31,33], and PKC in fibroblasts and cardiomyocytes [14,34]. Thus, one can hypothesize
that ONOO− acted via one of these signaling intermediates to activate the Raf-1/MEK/ERK
pathway in our experimental conditions.
The signaling properties of ONOO− may depend either on oxidative type of chemistry or on
the nitration of tyrosine residues, resulting in the formation of protein-bound 3-nitrotyrosine
[7]. Tyrosine nitration has been shown to impair tyrosine phosphorylation, thereby altering
various signaling processes (either activation or down-regulation) relying on tyrosine
phosphorylation [35]. The relative contributions of nitration and oxidation reactions in the
signaling events triggered by ONOO− can be distinguished using the flavanol (−)-epicatechin,
a compound inhibiting tyrosine nitration several orders of magnitude more efficiently than
oxidation reactions by ONOO− [15]. Stimulation of H9C2 cells with ONOO− induced a marked
nitration of cellular proteins that was dose-dependently inhibited by epicatechin (Fig. 7), in
agreement with previous findings [15]. However, epicatechin failed to inhibit ERK 1/2
Pesse et al. Page 6
J Mol Cell Cardiol. Author manuscript; available in PMC 2008 February 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
phosphorylation, implying that activation was not due to tyrosine nitration, but rather to an
oxidative chemistry. This is consistent with the recent proposal that oxidative inactivation of
tyrosine phosphatases by ONOO− [36] may be an important mechanism of signal transduction
triggered by ONOO−, by allowing kinase activities to become predominant [35].
In addition to ERK, we also show, for the first time, that ONOO− is a potent activator of the
phosphorlyation of two other MAPKs, JNK and p38, in cardiomyocytes (Figs. 8 and 9).
Similarly to the activation of ERK, p38 and JNK were phosphorylated in response to
ONOO− in a time- and concentration-dependent way. Both p38 and JNK have been correlated
with cardiomyocyte apoptosis [37,38], whereas ERK activation has emerged as an important
mechanism of cytoprotection able to delay or offset an apoptotic program [5,6]. Due to their
opposite effects, it is likely that the balance of activity of these distinct signaling pathways is
critical for the decision between cell demise or cell survival [6]. Importantly, all three
subclasses of MAP kinases have been shown to be activated in the human failing heart [39],
as well as in the heart of experimental animals following ischemia–reperfusion [40], conditions
in which ONOO− is currently considered a potential culprit of myocardial damage and
dysfunction [10,41]. The current data provide the new concept that ONOO− may not only be
a direct toxic effector in these circumstances, but may also be instrumental in the activation of
signal transduction pathways playing central roles in the mechanisms of apoptosis.
In summary, the present results represent the first experimental evidence that peroxynitrite
mediates ERK 1/2 activation in cardiomyocytes through a signaling cascade involving Raf-1
kinase and MEK 1, but which is independent from EGFR and p21Ras. The activation of MEK
1-ERK 1/2 by peroxynitrite is mediated by an oxidative, instead of nitrative, type of chemistry.
Our data also show that, in addition to ERK, peroxynitrite is able to activate p38 and JNK,
indicating that it can simultaneoulsy trigger anti- and pro-apoptotic signaling cascades in
cardiomyocytes. Given that myocardial peroxynitrite generation and MAP kinase activation
occur in similar pathological conditions, our findings indicate that peroxynitrite may represent
a previously unrecognized signaling molecule in a wide range of cardiac diseases.
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EGF  
epidermal growth factor
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EGF receptor
ERK  
extracellular signal-regulated kinase
JNK  
C-Jun NH2-terminal kinase
MAPK  
mitogen-activated protein kinase
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MAPK kinase
NO  
Pesse et al. Page 7
J Mol Cell Cardiol. Author manuscript; available in PMC 2008 February 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
nitric oxide
ONOO−  
peroxynitrite
O2−  
superoxide anion
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Fig. 1.
ONOO− induces the phosphorylation and the activity of ERK 1/2 in H9C2 cardiomyocytes.
A. Cells were treated with increasing concentrations of ONOO− for 15 min. Phosphorylation
of ERK 1/2 was induced at concentrations of ONOO− of 50 μM and above. Decomposed
ONOO− (DC) did not phosphorylate ERK. Total ERK was comparable in all the conditions of
stimulation. B. Cells were exposed to 500 μM ONOO− for 2–60 min. ERK phosphorylation
was maximally induced at 20 min of ONOO− exposure. C. Cells were either not stimulated
(NS) or activated with ONOO− (500 μM) or decomposed ONOO− (DC) for 15 min. ERK
activity was assessed by Elk-1 phosphorylation after immunoprecipitation of phosphorylated
ERK 1/2. As expected, ERK activity correlated with ERK phosphorylation. Densitometric
analyses are shown as mean ± S.E.M. of at least four independent experiments. * P < 0.05 vs.
NS.
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Fig. 2.
ONOO− induces the phosphorylation of ERK 1/2 in primary mouse ventricular
cardiomyocytes. Primary cardiomyocytes were either NS or treated with 500 μM ONOO− for
15 min. ONOO− induced a significant phosphorylation of both p42 and p44 MAP kinase.
Densitometric analyses are shown as mean ± S.E.M. of six independent experiments. * P <
0.05 vs. NS.
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Fig. 3.
ONOO− mediates ERK activation via MEK phosphorylation. A. MEK phosphorylation
induced in H9C2 cells exposed to ONOO− (500 μM) for 15 min. B. Cells were pretreated with
the MEK inhibitor PD98059 for 1 h and then activated with ONOO− (500 μM) for 15 min. The
phosphorylation of ERK 1/2 induced by ONOO− was significantly reduced by PD98059. NS:
not stimulated. Densitometric analyses are shown as mean ± S.E.M. of at least three
independent experiments. * P < 0.05.
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Fig. 4.
Distinct signaling pathways are involved in ERK phosphorylation elicited by EGF or
ONOO−. A. H9C2 cells were NS or treated with 0.1 μg ml−1 EGF for 15 min in the absence
or in the presence of AG1478 (100 nM), BAY 43–9006 (5 μM) or PD98059 (50 μM). The
phosphorylation of ERK 1/2 (p44/p42) induced by EGF was prevented by AG1478, BAY 43–
9006 or PD98059. B. Cells were NS or treated with ONOO− (500 μM, 15′) with or without
inhibitors. The activation of ERK 1/2 (p44/p42) induced by ONOO− was not influenced by
AG1478, but was prevented by BAY 43–9006 and PD98059. Densitometric analyses are
shown as mean ± S.E.M. of at least three independent experiments. * P < 0.05 vs. NS. † P <
0.05 vs. EGF. # P < 0.05 vs. ONOO−.
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Fig. 5.
MEK phosphorylation and ERK 1/2 activity induced by ONOO− are not dependent on EGFR
but depend on Raf-1 activation. Cells were either NS or were exposed to ONOO− (500 μM,
15 min) in the absence or in the presence of AG1478 (100 nM) or BAY 43–9006 (5 μM). MEK
phosphorylation (A) and ERK activity (B) were not influenced by AG1478, whereas they were
both suppressed in the presence of BAY 43–9006. Densitometric analyses are mean ± S.E.M.
of at least three independent experiments. * P < 0.05 vs. NS. † P < 0.05 vs. ONOO−.
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Fig. 6.
ONOO− does not activate Ras in H9C2 cells. Cells were NS or exposed to decomposed
ONOO− (DC, 5 min) or authentic ONOO− (500 μM, 2–15 min). Ras activation was assessed
as described in Section 2. A. A baseline activation of Ras was noted in untreated cells, that was
not further increased by ONOO−stimulation, whereas ERK 1/2 was phosphorylated in these
conditions. B. The phosphorylation of ERK triggered by ONOO− for 15 min was not influenced
by FPTII, a potent and selective inhibitor of Ras. C+, positive control; C– negative control.
Densitometric analyses are mean ± S.E.M. of four independent experiments. * P < 0.05 vs.
NS.
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Fig. 7.
ONOO− phosphorylates ERK 1/2 independently from tyrosine nitration. A. H9C2 cells were
stimulated with 500 μM ONOO− for 15 min in the absence or in the presence of increasing
concentrations of epicatechin (EC), an inhibitor of tyrosine nitration. ONOO− induced a
widespread nitration of tyrosine residues, that was dose-dependently inhibited by epicatechin.
B and C. Effects of epicatechin (100 μM) on the phosphorylation of ERK 1/2 by ONOO−. Cells
were either NS or stimulated with 500 μM ONOO− (15 min) with or without epicatechin (100
μM) pretreatment (1 h). ERK 1/2 (p44/p42) phosphorylation was not influenced by epicatechin.
Densitometric analyses are mean ± S.E.M. of four independent experiments. * P < 0.05 vs.
NS.
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Fig. 8.
ONOO− activates the phosphorylation of JNK in rat H9C2 cardiomyocytes. A. Cells were
either NS or treated with ONOO− at concentrations ranging from 50 to 1000 μM for 15 min.
JNK activation was monitored by Western blotting using specific antibodies against
phosphorylated JNK p46 and p54. Phosphorylation of JNK was triggered by ONOO− at
concentrations of 100 μM and above, with a maximum at 1000 μM. Total JNK1 was not
influenced by any of the conditions. B. Cells were NS or exposed to 500 μM ONOO− for 2 to
60 min. JNK phosphorylation started at 2 (p46) and 5 min (p54), peaked at 15–30 min and then
steadily declined at 60 min. NSB: non-specific band. Densitometric analyses are shown as
means of at least four independent experiments. * P < 0.05 vs. NS.
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Fig. 9.
ONOO− activates p38 phosphorylation in H9C2 cells. A. Cells were either NS or treated with
increasing concentrations of ONOO− and the level of phosphorlyated p38 was determined by
western blot. ONOO− dose-dependently phosphorylated p38 in a range of concentrations from
50 to 1000 μM, whereas it did not change the cell content in total p38. B. Treatment of cells
with 500 μM ONOO− activated p38 phosphorylation already after 2 min, with a peak at 15
min and a progressive decline up to 60 min, with no changes in total p38. Densitometric
analyses are shown as means of at least four independent experiments. * P < 0.05 vs. NS.
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